SYNE1 and neoplasm: CPG2 has previously been used in antibody-directed enzyme-prodrug therapy (ADEPT) in which it is targeted to tumours with tumour-specific antibodies (Bagshawe, 1990), an approach in clinical trial (Bagshawe et al, 1991; Napier et al, 2000).